Risk factors for secondary fractures in postmenopausal osteoporosis: A retrospective study. [PDF]
Zhang H, Du Y, Hu L.
europepmc +1 more source
Differential effects of romosozumab across central and peripheral skeletal sites: a prospective DXA and HR-pQCT study in high-risk postmenopausal osteoporosis. [PDF]
Chiba K +8 more
europepmc +1 more source
Performance of clinical prediction models for identifying postmenopausal osteoporosis: a systematic review and meta-analysis. [PDF]
Huang X +12 more
europepmc +1 more source
Construction of a nomogram prediction model for individualized prediction of vertebral compression fracture risk in postmenopausal osteoporosis population. [PDF]
Chen J, Wei B, Cai J, Lin H, Huang C.
europepmc +1 more source
Integrated Network Pharmacology and Proteomics Reveal That Erxian Decoction Counteracts Postmenopausal Osteoporosis via GSTA1-Mediated Oxidative Stress Suppression. [PDF]
Li J +8 more
europepmc +1 more source
miR-629-3p affects postmenopausal osteoporosis through targeted regulation of BACH1. [PDF]
Yun D, Zhang J, Ha S, Xiao J, Yan C.
europepmc +1 more source
Bisphosphonates in the Management of Patients with Postmenopausal Osteoporosis; Back to the Future. [PDF]
Papapoulos SE, Makras P.
europepmc +1 more source
Research Trends in Immunomodulatory Therapy for Postmenopausal Osteoporosis: A Bibliometric Analysis. [PDF]
Yi S +7 more
europepmc +1 more source
Follistatin-like protein 1 (FSTL1) modulates bone remodeling and attenuates bone loss in a mouse model of postmenopausal osteoporosis. [PDF]
Yuan H +6 more
europepmc +1 more source

